Minerva Neurosciences Inc Total Assets
Minerva Neurosciences Inc total assets. Based on the latest financial reports, Minerva Neurosciences Inc (NERV) holds total assets worth $94.03 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NERV stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Minerva Neurosciences Inc (2012–2025)
Total assets of Minerva Neurosciences Inc from 2012 to 2025. This chart illustrates how Minerva Neurosciences Inc's total assets have evolved over time, based on quarterly financial data. See NERV live share price for real-time trading data and today's change.
Minerva Neurosciences Inc - Asset Composition Analysis
Minerva Neurosciences Inc Total Assets Breakdown (December 2025)
Minerva Neurosciences Inc total assets breakdown as of December 2025. Minerva Neurosciences Inc's total assets of $94.03 Million consist of 84.8% current assets and 15.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $14.87 Million | 15.2% |
Asset Composition Trend (2012–2025)
This chart illustrates how Minerva Neurosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Minerva Neurosciences Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Minerva Neurosciences Inc's current assets represent 84.8% of total assets in 2025, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 84.0% of total assets in 2025, down from 95.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 15.2% of total assets.
Minerva Neurosciences Inc Competitors by Total Assets
Key competitors of Minerva Neurosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Minerva Neurosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.65 | 9.21 | 16.93 |
| Quick Ratio | 17.65 | 9.21 | 16.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $74.62 Million | $15.98 Million | $70.78 Million |
Minerva Neurosciences Inc - Advanced Valuation Insights
This section examines the relationship between Minerva Neurosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 1.12 |
| Asset Growth Rate (YoY) | 163.8% |
| Total Assets | $97.97 Million |
| Market Capitalization | $109.48 Million USD |
Valuation Analysis
Above Book Valuation: The market values Minerva Neurosciences Inc's assets above their book value (1.12x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Minerva Neurosciences Inc's assets grew by 163.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Minerva Neurosciences Inc (2012–2025)
The table below shows the annual total assets of Minerva Neurosciences Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $97.97 Million | +163.76% |
| 2024-12-31 | $37.14 Million | -34.72% |
| 2023-12-31 | $56.90 Million | +3.29% |
| 2022-12-31 | $55.09 Million | -28.57% |
| 2021-12-31 | $77.12 Million | +33.83% |
| 2020-12-31 | $57.63 Million | -25.64% |
| 2019-12-31 | $77.50 Million | -44.30% |
| 2018-12-31 | $139.14 Million | -24.26% |
| 2017-12-31 | $183.70 Million | +38.18% |
| 2016-12-31 | $132.94 Million | +60.99% |
| 2015-12-31 | $82.58 Million | +20.64% |
| 2014-12-31 | $68.45 Million | +134.62% |
| 2013-12-31 | $29.17 Million | +13838.62% |
| 2012-12-31 | $209.31K | -- |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in… Read more